Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Polyacrylic acid resin has a history that stretches back to the mid-20th century, a time of real hunger for better drug delivery systems. In pharmacy’s early days, pills broke up too fast or not fast enough, so scientists scoured for smarter ingredients. Out of all the options, acrylic polymers, with their water-loving carboxylic acid groups, offered a new kind of flexibility. By the 1970s, specialists in both Europe and the United States carved out technical standards under bodies like the BP, EP, and USP. Polyacrylic acid E30 earned a place thanks to its high purity and batch-to-batch reliability. The industry’s appetite for scaled-up, reproducible medicines kept this resin in high demand, and generations of researchers have kept tinkering to improve consistency and get rid of leftover monomers that sometimes crept into early resin supplies.
Polyacrylic acid resin E30 looks for all the world like a white, free-flowing powder or a coarse granule. The real value comes not from the appearance but how it functions. Inside tablets and gels, this resin works as a binding agent, a controlled-release backbone, or a thickener. Its BP, EP, and USP grades guarantee medical quality, which earns the trust of pharmaceutical developers and regulatory offices. Because it mixes easily with water and holds an impressive number of water molecules in its mesh, E30 can swell into gels or stay sturdy in harsher conditions, letting it stand out from other resins.
Polyacrylic acid E30 brings a specific set of physical and chemical traits to the table. It can absorb water—sometimes hundreds of times its own weight—and turn into a tough, clear gel. The powder itself likes to stay stable under ambient conditions if kept dry. Chemically, its backbone chains dangle carboxylic acid groups ready to pick up hydrogen ions, which matters for how it behaves in the gut or bloodstream. Molecular weights for pharma-grade resin often hover in the range of hundreds of thousands to several million Daltons. These long tangled molecules let the resin trap water, control viscosity, and form films. The structure also absorbs ions and can react with a wide range of pharmaceutical actives, rather than staying inert or unpredictable under normal storage and mixing.
Every drum or pouch of Polyacrylic acid E30 sold as BP, EP, or USP pharmaceutical grade promises minimum purity standards, low residual solvent content, and a tight window for molecular weight. Documentation includes the lot number, clear references to compendial standards, and the expiration date, not just for paperwork but as real assurance for buyers. On the label, details about recommended storage, pH range, ash content, and loss on drying bring extra transparency. Routine sampling and batch records back up claims, because audit trails really matter for hospitals and regulators. These clear labels keep mistakes at bay and support any downstream testing or recalls.
Production of Polyacrylic acid resin E30 starts with the free-radical polymerization of acrylic acid, usually under nitrogen to keep oxygen out, as oxygen would ruin the reaction. A water-based process keeps it green, since dangerous solvents and excessive waste spark regulatory backlash. Initiators like hydrogen peroxide or potassium persulfate set off the chain reaction, linking monomers into long, strong chains. Technicians fine-tune factors like temperature, mixing rate, and initiator concentration to get polymer chains long enough but not too tangled. After polymerization finishes, the raw product runs through multiple washes to strip out unreacted acid, and then a drying step brings the powder to spec. Modern plants recycle water and reuse solvents where possible, trimming costs and shrinking their environmental footprint.
Polyacrylic acid E30 doesn’t stop at just soaking up water or thickening up a formulation. The carboxylic acid groups can be neutralized with sodium, potassium, or ammonium hydroxide, creating salts with different swelling and gel-forming abilities. Chemists have also grafted other polymers onto the backbone to tweak how the resin dissolves or interacts with drugs and excipients. Sometimes cross-linking is introduced by adding small molecules that tie polymer chains together, making for ultra-tough gels that release medicine slowly over hours or even days. Pharmaceutical formulators count on these modifications to match each drug’s release needs—rapid, sustained, or with a specific pH trigger like the gut or stomach.
Polyacrylic acid E30 often goes by several recognized names in science and business. Pharmaceutically, it turns up as Carbomer, Carbopol, or Acrylic Acid Polymer. Suppliers list it under catalog names like PAA E30, Sodium Polyacrylate, or just Polyacrylate Resin. Regulatory documents usually tag the resin with either its INCI name or direct reference to compendial monographs. This variety can trip up buyers new to the industry, teaching a lesson in carefully reading certificates of analysis and product data sheets.
Safe handling of Polyacrylic acid E30 relies on clear rules in production plants and pharmacies. Inhalation of powder is a risk, so most sites use dust extractors and encourage gloves, masks, and sealed containers. Spills clean up easily with water but create slippery floors, so training ground staff makes a difference. BP, EP, and USP grades guarantee that harmful monomers sit well below detection or toxicity limits, often below 10 parts per million. Workers receive regular training on how to move, mix, and dispose of the resin, and quality assurance samples run for microbial counts and heavy metal contamination. Proper labeling on all packs and documentation for at least several years means incidents stay rare, and investigations happen fast.
Pharmaceutical developers lean on Polyacrylic acid E30 across tablets, capsules, gels, and topical creams. In sustained-release tablets, its swelling habit creates a barrier that slows how drug molecules drift out, improving patient compliance and reducing side effects from ups and downs in blood levels. Dental products use the resin as a binder in cements and adhesives, taking advantage of its non-toxic reputation at clinical doses. Some eye gels use the resin for viscosity, holding active ingredients on the eye longer than water or salt solutions. Outside pharmacy, some medical device coatings and transdermal patches depend on the sticky, water-laden gels to keep medicines near the skin for hours.
Research into polyacrylic acid E30 never really stops. Labs work on new cross-linking chemistries to get even finer control on swelling and drug release. Nanotechnology teams play with blending E30 into nanoparticle systems to protect fragile molecules from stomach acid. For gene and peptide delivery, scientists work on tuning the chain length and branching to avoid immune reactions while keeping delivery precise. Even with decades of FDA and EMA acceptance, researchers continue to make the resin safer, more biodegradable, and less prone to trapping unwanted molecules during synthesis. Academic institutions publish reviews every year on new and niche uses, pushing formulators to adapt old tools to modern precision therapeutics. Collaboration between raw material firms and drug companies reinforces a continuous feedback loop for safer, smarter, and more cost-effective products.
Most toxicity studies confirm that pharmaceutical grade Polyacrylic acid resin rarely triggers acute or chronic harm at clinical doses. Animal studies find that the resin passes through the gut largely unchanged and doesn’t accumulate in tissues. Allergic reactions remain rare, especially compared with natural polymers like gelatin. Early safety concerns around left-over acrylate monomers have driven improvements in agency standards and testing methods. Recent research explores the long-term effects of microplastics, but at pharmaceutical doses, evidence suggests a large margin of safety. Still, companies keep an eye on the latest toxicological data, since regulatory agencies like the FDA and EMA update acceptable daily intake levels as new research emerges. Every new modification gets a close scan for metabolic byproducts or changes in absorption, so risks stay in check even as old ingredients meet new needs.
Looking ahead, Polyacrylic acid E30 stands at the intersection of tradition and technological innovation. The world of controlled-release drugs keeps demanding smarter materials, pushing researchers to create resins that respond not only to pH but temperature, specific enzymes, or even electric charges. Biodegradability is making waves, especially as single-use tablets and medical devices grow more popular worldwide. Companies chase greener, more ethical production that shrinks both resource use and waste. AI-driven formulation is starting to show that small tweaks to polymer structure can lead to big leaps in drug delivery and patient outcomes. For the foreseeable future, the resin sits poised to serve existing therapies and anchor the next wave of advanced drug formulations.
Polyacrylic Acid Resin E30, produced to meet BP, EP, and USP standards, serves a specific role in modern medicine. In my own time around formulation labs and regulatory teams, I’ve seen this resin come up whenever controlled release or stability is a concern. Makers of tablets and capsules consistently look for ways to release medicine at the right spot in the body and at the right pace. Polyacrylic Acid Resin, with its ability to swell and form gels, offers a concrete solution.
Take oral solid dosage forms. A tablet going through the harsh acidic environment in the stomach can lose potency or irritate the patient. Here, Polyacrylic Acid Resin serves as an enteric coating. I’ve watched teams coat aspirin and proton pump inhibitors with this resin so the drug survives stomach acid and dissolves further down the digestive tract, where it’s meant to work. Clinical studies and regulatory filings show fewer GI side effects and improved drug stability with such approaches.
Many medicines require a slow, predictable release. Gel-forming properties of Polyacrylic Acid Resin make it a choice excipient for matrix tablets and extended-release capsules. Once the tablet reaches the gut, the resin absorbs water, swelling to form a gel barrier. This slows down the movement of active drug, extending how long it lasts in the body. Extended-release forms help patients avoid peaks and troughs in their medicine levels, cutting down side effects and visits to the pharmacy.
Not every drug comes as a solid pill. Many antibiotics, antacids, and painkillers arrive as liquid suspensions. Consistency in dosing relies on all ingredients being evenly dispersed every time a dose is poured. Here, Polyacrylic Acid Resin “locks” particles in place through formation of a microgel matrix. From pharmacy counters to clinical practice, this keeps doses predictable and avoids clumping.
Ointments and gels for skin problems also take advantage of Polyacrylic Acid Resin. Think wound gels, acne treatments, or even sunburn relief. As a thickening and stabilizing agent, this resin yields non-irritating, smooth textures. I’ve talked to compounding pharmacists who rely on it to prevent creams from separating while staying easy to apply.
Polyacrylic Acid Resin doesn’t just make drugs easier to manufacture. By supporting enteric coatings and extended release, it helps patients bypass side effects, stick to their medication schedules, and get better treatment outcomes. For young children, the elderly, or anyone sensitive to GI irritation, these advances matter. Simple improvements like these cut prescription abandonment and hospital readmissions.
No tool is perfect. Regulatory agencies demand detailed safety data, since Polyacrylic Acid can affect how the body absorbs certain medicines. Selecting the right particle size and type involves hands-on testing. In large-scale projects, teams face pressure to keep costs down and process controls tight to guarantee batch-to-batch performance. Efficient training, data transparency, and routine quality audits form the backbone of safe adoption.
As research moves forward, pharmaceutical scientists explore new grades and blends of Polyacrylic Acid Resin. Some labs look into personalized dose-dispensing or “smart” coatings that respond to changes in the gut. In any case, this resin bridges science and patient need with a real impact across the healthcare world.
Polyacrylic Acid Resin E30 is a staple for anyone who’s worked up close with polymers, adhesives, or water-soluble resins. Its molecular weight actually sets the groundwork for its many uses. The average molecular weight for E30 tends to fall around 450,000 g/mol. Compare this to lower-MW acrylic resins, and you’ll notice how E30 comes out thicker, more robust, and easier to control for certain thickening or suspending jobs.
I’ve seen labs and production floors where the difference between products boiled down to the right MW. E30 isn’t just a random blend—it’s built for those who need a strong backbone in their formulation. Lower weights can mean more fluidity, which might sound convenient, but it doesn’t always give you the hold or film strength needed in paints or gels. Look at acrylic dispersants, and you notice how that molecular weight influences whether a product keeps its shape or turns watery.
Viscosity isn’t only a number you glance at on a data sheet. For E30, the viscosity usually lands between 30,000 and 40,000 mPa·s (millipascal-seconds) in a 20% aqueous solution at room temperature. I remember struggling with a batch in the past where the wrong viscosity ruined an entire roll of coated textile—product sagged, dripped, and failed to cure evenly.
E30’s viscosity has practical roots. It creates the right spread or body in paints and cosmetics. I’ve personally seen how a slight bump up in viscosity kept hand gels from sliding off skin, letting the active ingredients work longer. In adhesives or paper coatings, high viscosity controls penetration and sets drying times, playing right into processing windows and cost savings. It’s a balance—too thick, you waste time and energy; too thin, you risk product failure or customer complaints.
With today’s environmental and quality standards, knowing the molecular weight and viscosity down to the digit isn’t a luxury—it’s a requirement. Customers and regulators ask for these details. You don’t want batch-to-batch surprises, whether you’re stabilizing a mineral slurry or thickening a personal care product.
Someone running production wants consistency. If you underdose on MW or get the viscosity wrong, you could see separation, precipitation, or even recalls. Raw numbers are only part of the story. Dry and wet handling, compatibility with other ingredients, and how E30 reacts during storage all circle back to molecular design and viscosity.
Getting better performance out of E30 means regular QC checks. Test the molecular weight using gel permeation chromatography—solid, reliable, and precise for tracking chain length. Measure viscosity at the same concentration you use in your formulas; temperature can swing readings wildly, so stick to standard conditions.
Mixing experience with precision pays off. Adjust pH or dilution for real-time tweaks. Maybe blend with a lower-MW acrylic for custom viscosity, or use different neutralizing agents (like sodium hydroxide or ammonia) to tune flow. Supplying thorough specs and batch data to partners sets the stage for fewer surprises. It helps to keep a close relationship with both the supplier and the tech team—don’t wait until there’s a failed batch to find out how E30 really works.
Regulations tighten and customers expect more every year. Polyacrylic Acid Resin E30 stands up because it hits the mark on molecular weight and viscosity. Knowing the numbers and learning from every run gives you safer, more predictable product—and builds trust that’s hard to earn any other way.
Polyacrylic acid resin E30 finds its way into many pharmaceutical products. You might encounter it in tablet coatings or as a controlled-release agent. The draw comes from its swelling capacity, which makes it good at holding onto water and controlling drug release. These qualities turn it into a key part of how tablets behave once swallowed.
Pharmaceutical quality isn’t just about how well a product works. Safety, compliance, and purity matter just as much, if not more. In this industry, every material counts. Meeting standards like BP (British Pharmacopoeia), EP (European Pharmacopoeia), and USP (United States Pharmacopeia) isn’t just red tape. It’s about trust—both from regulators and, more importantly, from patients.
BP, EP, and USP don’t just check off a list of chemical properties. Their rules run deep, diving into aspects like heavy metal content, microbial contamination, and residual solvents. They set limits for substances that can cause harm, especially when medications reach the vulnerable: children, the elderly, or the immunocompromised. Each standard adds a layer of security, and being compliant isn’t up for debate.
A resin labeled “E30” doesn’t automatically mean it checks all these boxes. Companies prove compliance through rigorous lab tests, including identity verification, solubility testing, pH measurement, viscosity, and heavy metal screening. Only clear and complete certificates of analysis can show whether a batch tracks with BP, EP, and USP requirements.
Shortcuts in testing or documentation open doors to real-world problems. Residual monomers or heavy metals don’t announce themselves in a finished product, but they can trigger allergic reactions, kidney damage, or worse. Even pricier quality control steps can get skipped if supply chains grow too tangled. Reports continue to surface about products contaminated with harmful levels of impurities. If E30 resin falls short, that risk doubles for patients who rely on accuracy and purity.
Producers with a reputation to protect embrace full transparency. They share batch-specific certificates and test results. Peer-reviewed studies contribute hard data about polyacrylic acid’s long-term biocompatibility. The best suppliers undergo regular on-site audits rather than relying solely on paperwork.
Regulators push for tighter traceability. Some countries now demand digital records and barcodes to track every ingredient from origin to finished dose. This accountability keeps the stakes high for anyone handling E30 resin along the chain.
Manufacturers picking a resin supplier should dig past marketing pitches. Ask for documented compliance with BP, EP, and USP standards. Scrutinize test reports for every batch. Discuss typical and maximum allowable levels of lead, arsenic, or other contaminants. Practically, ignoring these questions can endanger patients and trigger drug recalls.
As a pharmacist, I’ve seen firsthand how clear documentation reassures both staff and customers. When doubts arise about excipients, health professionals return unopened stock, demand fresh supply, or call in the supplier for reassurance. Patients deserve nothing less.
Moving forward, I hope more pharmaceutical players embrace a zero-compromise attitude. Safe and compliant polyacrylic acid resin isn’t just another box to tick; it stands as a promise to the people swallowing those tiny tablets every day.
Polyacrylic Acid Resin E30 plays an important role in manufacturing fields like adhesives, coatings, and pharmaceuticals. For anyone working with chemical resins, storage isn’t just a matter of free space on a shelf. Proper storage decisions save raw materials and cut down on unnecessary costs. The quality of the final product often traces back to how the raw resin gets handled right after delivery.
From my own time working in a medium-sized lab, I’ve seen one small mistake ruin an entire batch. Polyacrylic Acid Resin E30, in particular, comes as a white powder or granular form. This resin reacts very quickly to moisture. Even a short exposure to humidity can clump things up or trigger unwanted reactions. Once a bag shows clumping or any odd discoloration, you can bet it isn’t up to spec.
Companies and suppliers agree: keep Polyacrylic Acid Resin E30 sealed tight, away from damp air. To get the most out of every batch, it’s best to store it in a cool, dry room. Direct sunlight should never hit the storage area—UV rays have a way of sparking chemical changes you won’t spot until you mix up your formula.
The sweet spot for storage lies between 5°C and 30°C (41°F to 86°F). Higher temperatures kick off degradation, which slowly cuts down performance and shelf life. Cold rooms work too, so long as condensation is avoided during the resin’s “warm up” to room temperature before use. Any window for moisture to sneak in—even just a few minutes during repackaging—can shorten that optimal shelf life.
Workers in busy labs sometimes cut corners, tossing partially used resin bags back on the shelf without tightly resealing. I’ve seen this practice multiply waste and double the ordering budget. Dedicated, airtight containers with desiccant packs block moisture and maintain quality. Labeling every container with the opening date and lot number cuts out confusion in the rush of daily workflow.
In typical storage conditions, Polyacrylic Acid Resin E30 holds steady for about two years after production. The manufacturer’s date on the bag isn’t just a suggestion. Beyond those two years, the resin slowly loses its punch. Water absorption, exposure to air, and dirt from repeated handling speed up that process.
Some folks might try pushing expired resin into production. Based on my experience, this choice often leads to batch rejection and downtime. Chemical breakdown can show up as changes in viscosity, unexpected reactions, or even a strange smell. It pays to follow clear “first-in, first-out” rotation and discard old stock. Otherwise, you risk dead weight on your inventory and unreliable final products.
Polyacrylic Acid Resin E30 isn’t just another line item on a safety data sheet. It represents both cost and quality in daily production. Each worker’s attention to sealing, labeling, and maintaining the right temperature and humidity pays off. Building these habits doesn’t call for expensive equipment. Most of us simply need clean airtight bins, desiccant packs, log sheets, and a basic thermometer.
The better the storage practices, the less you throw away. Reliable inventory means fewer headaches on the production line and more consistent results for clients and customers downstream.
Polyacrylic acid resin E30 turns up in pharmaceutical conversations for a reason. Working in the field, it's impossible to ignore the demands for tablets that don't dump drug right at the start. People want medications that last through a commute, a work shift, or a long night, not peaks and valleys of effect. Polyacrylic acid, with its strong swelling in water and the way it forms a gel matrix around drug particles, gives formulators a fighting chance to slow things down in the gut.
E30 brings real credibility thanks to its carboxyl-rich backbone. Water in the digestive tract swells the resin into a thick mesh. This mesh forces water and digestive juices to squeeze through tiny tunnels before getting to the drug inside. It acts as a kind of security guard, letting the tablet release its payload only as the mesh breaks down or erodes. Compared to basic starch binders or sugar coatings, this resin puts more control into a pharmacist’s hands.
Pharmacists and techs I've spoken to appreciate how predictable polyacrylic acid behaves during high-speed tableting. The consistency shines, especially for those wrestling with drugs that need a steady hand—think diabetes or heart medications. E30 offers resistance to sudden pH swings, so drug release stays dependable despite what someone ate for breakfast. That trait matters every day in clinics and pharmacies everywhere.
Polyacrylic acid does more than just stretch out a drug’s time window. Sometimes, older tablets drop most of their drug in the stomach, where acid or enzymes chew up what’s there. E30 can shield sensitive drugs until they reach less harsh parts of the intestine, improving how much medicine survives the trip. That protective trick helps medications do their job, translate into better outcomes, and builds trust between patients and care teams.
Plenty of published research backs the use of E30 as a release-control agent. The FDA recognizes its safety at regulated doses. No material enjoys a free ride—your team must watch out for individual allergies and the tablet context—but overall, it has done well on toxicity, long-term exposure, and the gut's tolerance.
Of course, no one formulation solves every challenge. Polyacrylic acid struggles with drugs that need to dissolve instantly. Sticky climates or careless packaging can lead to moisture absorption and clumping. If a patient takes high-fiber diets or certain antacids, even the best E30 matrix can crack under too much pressure. I’ve seen cases where it held up well enough for most, but not all, patient lifestyles.
Some answers lie in blending E30 with other polymers. The drug industry picks up lessons fast, mixing tech from different parts of the world to fit every pill’s job. Smarter coatings, combined excipients, or tweaks to tablet compression all push control further. Researchers now test crosslinking E30, aiming for tougher gels that don’t quit early in the gut, and exploring particle size adjustments for tailored release rates.
People outside the lab may not care about excipient chemistry, but anyone who’s forgotten a pill dose or waited hours for relief gets the difference controlled-release makes. Polyacrylic acid resin E30 stands out by delivering what folks expect: steady, reliable therapy that fits busy lives. No magic bullet exists, but this resin adds another reliable tool for real-world medicine.
| Names | |
| Preferred IUPAC name | poly(1-carboxyethylene) |
| Other names |
Carbopol 934 Carbomer Acrylic Acid Polymer Carbomer 940 Poly(acrylic acid) Acrylic Resin |
| Pronunciation | /ˌpɒli.əˈkrɪl.ɪk ˈæs.ɪd ˈriː.zɪn iː ˈθɜːti ˌbiːˈpiː ˌiːˈpiː ˌjuːˈɛsˈpiː ˈfɑː.mə ɡreɪd/ |
| Identifiers | |
| CAS Number | 9003-01-4 |
| 3D model (JSmol) | `C([C](C(=O)O)*)*` |
| Beilstein Reference | 9033-79-8 |
| ChEBI | CHEBI:53473 |
| ChEMBL | CHEMBL1200748 |
| ChemSpider | 29435621 |
| DrugBank | DB11097 |
| ECHA InfoCard | 03beaba7-8eb3-475c-8666-fb8eb6b60e67 |
| EC Number | 9003-01-4 |
| Gmelin Reference | 132132 |
| KEGG | C01620 |
| MeSH | Dental Materials |
| PubChem CID | 107567 |
| RTECS number | TRW40206MV |
| UNII | 71R8FD7305 |
| UN number | UN3077 |
| Properties | |
| Chemical formula | (C3H4O2)n |
| Molar mass | 72.06 g/mol |
| Appearance | White to off-white powder |
| Odor | Odorless |
| Density | 1.22 g/cm³ |
| Solubility in water | Freely soluble in water |
| log P | -0.82 |
| Acidity (pKa) | 4.5–5.0 |
| Basicity (pKb) | 6.2 |
| Magnetic susceptibility (χ) | -7.9×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.48 |
| Viscosity | 800 - 1500 mPa.s (10% solution) |
| Dipole moment | 2.91 D |
| Pharmacology | |
| ATC code | A01AB11 |
| Hazards | |
| Main hazards | May cause eye, skin, and respiratory irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS05,GHS07 |
| Signal word | Warning |
| Hazard statements | No hazard statements. |
| Precautionary statements | Precautionary statements: P264, P280, P305+P351+P338, P337+P313 |
| NFPA 704 (fire diamond) | 2-1-0 |
| Flash point | > 250°C |
| Autoignition temperature | > 400°C |
| LD50 (median dose) | > 6400 mg/kg (Rat, oral) |
| PEL (Permissible) | 10 mg/m³ |
| REL (Recommended) | Not more than 0.5% |
| IDLH (Immediate danger) | No IDLH established. |
| Related compounds | |
| Related compounds |
Acrylic acid Polyacrylamide Sodium polyacrylate Polymethyl methacrylate Carbomer Polysodium acrylate Polyacrylonitrile Polyvinyl alcohol Polyethylene glycol |
Chengguan District, Lanzhou, Gansu, China
